 Home > Medical News > Medicines Company News > Drug costs are too high!

Drug costs are too high!

 Last Update: 2021-07-06
 Source: Internet
 Author: User

Tags

fluid loss

what expensive drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 3, according to foreign media reports, Roche’s oral spinal muscular atrophy (SMA) drug Evrysdi was too expensive to be approved by the UK drug price regulator
.

The United Kingdom's Drug Cost and Efficacy Management Agency (NICE) has issued a draft guideline that does not recommend the use of Roche's risdiplam (marketed as Evrysdi) for patients with type 1, 2 and 3 SMA

NICE stated that SMA is a progressive neuromuscular disease that affects the spinal nerves that control movement.
It can cause muscle weakness, progressive loss of exercise capacity, and difficulty breathing and swallowing
.

If recommended, approximately 1,500 people will be eligible for the drug

Nevertheless, the agency recognizes that oral administration of Evrysdi makes it a better choice for some patients
.

Evrysdi is the third SMA drug approved in recent years, second only to Biogen's Spinraza and Novartis' gene therapy Zolgensma

NICE currently recommends Spinraza for pre-symptomatic SMA patients or patients with type 1, 2 or 3 disease
.

The cost of the drug was 450,000 pounds in the first year and 225,000 pounds in subsequent years, but NICE and Biogen signed a confidentiality discount agreement

The agency's decision may trigger further discussion
.

NICE said it will listen to opinions before June 23 and will meet again on July 13

Reference source: Roche's oral SMA med Evrysdi turned down by UK cost watchdog—despite prior nods for Zolgensma and Spinraza

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.